---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-067061"
form_type: "8-K"
ticker: "NMTC"
cik: "0001500198"
company_name: "NEUROONE MEDICAL TECHNOLOGIES Corp"
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:51:24.105943+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroOne Q3 FY2023 product revenue $630K, up from $32K; net loss $3.5M

## Summary
- Product revenue $630K in Q3 FY2023 vs $32K YoY; collaboration revenue $1.46M in 9M.
- Net loss $3.5M in Q3 vs $2.8M prior year; cash $3.1M at June 30 vs $8.1M at Sept 30.
- Evo sEEG limited launch completed; full launch with Zimmer Biomet expected Q4. OneRF 510(k) submitted June 8.
- Closed public offering net $5.2M and ATM net $2.5M in July 2023; no debt.

## SEC filing metadata
- accession: 0001213900-23-067061
- form_type: 8-K
- ticker: NMTC
- cik: 0001500198
- company_name: NEUROONE MEDICAL TECHNOLOGIES Corp
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1500198/000121390023067061/0001213900-23-067061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1500198/000121390023067061/ea183383-8k_neuroone.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-067061
- JSON: https://secwatch.observer/filing/0001213900-23-067061.json
- Plain text: https://secwatch.observer/filing/0001213900-23-067061.txt

## Key facts
- Earnings Releases
  NEUROONE MEDICAL TECHNOLOGIES Corp reported fiscal third quarter 2023 ended June 30, 2023 results: revenue Product revenue was $630,000 in the fiscal third quarter 2023, net income Net loss was $3.5 million for the fiscal third quarter 2023.
  - Period: fiscal third quarter 2023 ended June 30, 2023
  - Revenue: Product revenue was $630,000 in the fiscal third quarter 2023
  - Net income: Net loss was $3.5 million for the fiscal third quarter 2023
  - Result: reported results
  source text: On August 14, 2023, NeuroOne Medical Technologies Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1500198/000121390023067061/0001213900-23-067061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.